An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101
← catalyst calendarNCT06867107 · readout in 11 d
Sponsored by Satellos Bioscience, Inc. (industry) · MSLE — their whole pipeline →.
Phase
Phase 2
Status
Enrolling by invitation
Study type
Interventional
Design
Na · None · Treatment
Enrollment
10estimated
Sites
2
Country
Australia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-20 | actual | When the study began enrolling |
| Primary completion | 2026-08-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-08-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Duchenne Muscular Dystrophy (DMD)
Intervention
- Drug: SAT-3247
Primary outcome
what the primary-completion date above is the date OFTreatment emergent adverse events
measured 11 months
Permalink · MSLE's whole pipeline · Catalyst calendar · Every registered study · What changed